An interventional study of Standard Low FODMAP dietary regimen and personalized low FODMAP dietary regimen in Irritable Bowel Syndrome, sponsored by Weizmann Institute of Science. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Weizmann Institute of Science · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Irritable Bowel Syndrome with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Israel.
Among the 11 studies in Irritable Bowel Syndrome with a site in Israel, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →2 of the 11 studies in Irritable Bowel Syndrome with a site in Israel are open now. Recruiting first, the newest first:
Ariel University · Sites in Israel
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 30 is below the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 110 across the 10 interventional studies, 440,822 across the 1 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 10 most frequent:
Weizmann Institute of Science is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
Weizmann Institute of Science has 1 study filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Irritable Bowel Syndrome with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.
This interventional study will include volunteers who are suspected of suffering from IBS. They will be asked to fill several questionnaires: Rome IV Diagnostic Questionnaire for Irritable Bowel Syndrome (R4DQ), irritable bowel syndrome - Symptom Severity Scale (IBS-SSS), irritable bowel syndrome - Quality of Life survey (IBS-QOL) and a food frequency questionnaire (FFQ). Blood tests including Celiac serology will be taken, as well as stool for home Calprotectin test. participants will be asked to collect stool samples at home.
If the participant has a recent, relevant medical documents, they will be asked to provide them to the study team for further evaluation of IBS diagnosis.
Gastroenterologist will receive anonymized patients data - for validation and final diagnosis of IBS.
At the end of the screening period, participants without a gastroenterologist's approval - will end their participation in the study, whereas participants who will be deemed fit, will continue to the next phase and will be allocated randomly to one of the two arms to start the nutritional intervention:
Participants will be asked to record daily activities, food intake, Bristol stool scale, and symptoms on a smartphone application during the elimination and reintroduction phases. Participants will be given kits to collect stool samples at home during all study phases.
The dietitian follow-up meetings will be held on a weekly basis during the elimination and re-introduction phases via phone/video call or frontal meeting. Dietitian counseling will include the Monash University's low FODMAP diet app guidance.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
individuals that are diagnosed with IBS according to Rome IV criteria Standard low FODMAP dietary regimen randomized re-introduction phase
Other: Standard Low FODMAP dietary regimen
individuals that are diagnosed with IBS according to Rome IV criteria FODMAP dietary regimen with personalized re-introduction phase
Other: personalized low FODMAP dietary regimen
Standard low FODMAP dietary regimen randomized re-introduction phase
Low FODMAP dietary regimen with personalized re-introduction phase
Stool microbiome composition
metagenomic sequencing of stool samples
Time frame: 4 months
IBS-SSS - irritable bowel syndrome severity score system questionnaire
Severity of symptoms as they are scored in the Rome IV IBS-SSS 75 to \<175 to indicate mild IBS, 175 to \<300 as moderate, and \>300 as severe
Time frame: 4 months
IBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaire
Quality of life scores from the Rome IV IBS-QOL 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life
Time frame: 4 months
Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.
Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 20 months is close to that.
Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weizmann Institute of Science